Abstract:Background: DExD-box helicase 21 (DDX21) is an essential member of the RNA helicase family. DDX21 is involved in the carcinogenesis of various malignancies, but there has been no comprehensive research on its involvement in different types of cancer. Method: This study used TCGA, CPTAC, GTEx, GEO, FANTOM5, BioGRID, TIMER2, GEPIA2, cBioPortal, STRING, and Metascape databases and Survival ROC software to evaluate DDX21 gene expression, protein expression, immunohistochemistry, gene mutation, immune infiltration, and protein phosphorylation in 33 TCGA tumor types, as well as the prognostic relationship between DDX21 and different tumors, by survival analysis and similar gene enrichment analysis. Furthermore, Cell Counting Kit-8 (CCK-8) and Transwell studies were employed to assess the effect of DDX21 expression on lung adenocarcinoma (LUAD) cell proliferation and migration. Result: The DDX21 gene was highly expressed in most cancers, and overexpression was associated with poor overall survival (OS) and disease-free survival (DFS). DDX21 mutations were most common in uterine corpus endometrial carcinoma (UCEC; >5%), and DDX21 expression was positively correlated with the degree of infiltration of CAF and CD8 + cells in several tumor types. Numerous genes were co-expressed with DDX21. Gene enrichment analysis revealed close links between DDX21, RNA metabolism, and ribosomal protein production. In vitro analysis of LUAD cells showed that DDX21 expression was positively correlated with cell proliferation and migration capacity, consistent with prior bioinformatics studies. Conclusions: DDX21 is overexpressed in a variety of cancers, and overexpression in some cancers is associated with poor prognosis. Immune infiltration and DDX21-related gene enrichment analyses indicated that DDX21 may affect cancer development through mechanisms that regulate tumor immunity, RNA metabolism, and ribosomal protein synthesis. This pan-cancer study revealed the prognostic value and the oncogenic role of DDX21.

The roles of RNA helicases in DNA damage repair and tumorigenesis reveal precision therapeutic strategies

Supplementary Data from the Roles of RNA Helicases in DNA Damage Repair and Tumorigenesis Reveal Precision Therapeutic Strategies

Current understanding of the role of DDX21 in orchestrating gene expression in health and diseases

Widespread genomic/molecular alterations of DNA helicases and their clinical/therapeutic implications across human cancer

Pan-cancer analysis identifies RNA helicase DDX1 as a prognostic marker

DEAD-Box RNA Helicases in Cell Cycle Control and Clinical Therapy

DNA damage response-related ncRNAs as regulators of therapy resistance in cancer

Roles of DDX5 in the Tumorigenesis, Proliferation, Differentiation, Metastasis and Pathway Regulation of Human Malignancies

DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression

DEAD-box RNA helicases in the multistep process of tumor metastasis

Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence

High Levels of DEAH-Box Helicases Relate to Poor Prognosis and Reduction of DHX9 Improves Radiosensitivity of Hepatocellular Carcinoma

DDX41 Regulates the Expression and Alternative Splicing of Genes Involved in Tumorigenesis and Immune Response

Effects of DDX Family on Cancer Development and Progression

A Double-Edged Function Of Ddx3, As An Oncogene Or Tumor Suppressor, In Cancer Progression

LncRNAs in DNA Damage Response and Repair in Cancer Cells

The emerging role of RNAs in DNA damage repair

Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types

LncRNAs in DNA damage response and repair in cancer cells.

The putative RNA helicase DDX1 associates with the nuclear RNA exosome and modulates RNA/DNA hybrids (R-loops)

Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease